Life Sciences Venture Fund aMoon Closes Second Fund at $660 Million
The second fund will focus on mid to late-stage health companies in the domains of pharma, digital health, and medical technology
10:0006.03.19
Israel-based life sciences, healthcare, and technology venture capital firm aMoon is closing its second fund, aMoon II, at $660 million, the company announced Wednesday.
Digital health (illustration). Photo: Shutterstock
For daily updates, subscribe to our newsletter by clicking here.
Reuters reported the fund had $600 million in commitments in January. AMoon reported a $250 million commitment from Credit Suisse AG in May.
Digital health (illustration). Photo: Shutterstock
AMoon was founded in 2016 by Yair Schindel, the former CEO of an Israeli government agency in charge of pushing forward digital initiatives, and Marius Nacht, the co-founder of firewall pioneer Check Point Software Technologies Ltd. Its first fund was backed exclusively by Nacht.
Related stories:
- Life Sciences Venture Fund aMoon Raises $600 Million for Second Fund, Report Says
- Life Sciences Venture Fund aMoon Nearing Cap of Second Fund, Says Co-Founder
- Credit Suisse to Invest $250 Million in Israel-based Life Sciences Venture Fund aMoon
The second fund will focus on mid to late-stage health companies in the domains of pharma, digital health, and medical technology, making investments in the range of $10 million to $50 million over the next five years in 15-20 startups.
AMoon's current portfolio companies include Israel-based DayTwo Ltd., which analyzes gut microbiomes to personalize dietary recommendations, and medical analytics company Zebra Medical Vision Ltd.
